drugset
drugset / Trial / NCT04907851

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

NCT04907851 ↗

Phase 2 Completed 45 enrolled Redx Pharma Ltd Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy and in combination with pembrolizumab in advanced solid tumours that have progressed following SoC treatment.

Timeline

Start
2021-12-10
Primary completion
2023-11-30
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ZAMAPORVINT Small molecule 1 mg Oral
Subject ZAMAPORVINT Small molecule 1.5 mg Oral
Subject ZAMAPORVINT Small molecule 2 mg Oral
Background Denosumab Monoclonal antibody 120 mg Subcutaneous
Background Pembrolizumab Monoclonal antibody 400 mg Intravenous

Indications

cancer